Naomi Haas, MD, discusses the 5-year follow-up of the KEYNOTE-564 study being presented at the 2025 ASCO Annual Meeting.

Bispecific anti-PD1/VEGF remains one of the hottest topics in the oncology field. Click here for a detailed analysis.

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an ...

The results show an impressive 63% objective response rate (ORR) in 43 evaluable patients in a phase 2 trial, as of a 27th ...

A new review was published in Volume 16 of Oncotarget on May 19, 2025, titled “Advancements in bladder cancer treatment: The ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and ...

N.V. “announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

The revision comes after encouraging Phase 2 data for Merus’ drug candidates petosemtamab and pembrolizumab (pembro) were ...

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...